Harren Jhoti

Dr. Harren Jhoti is a co-founder of Astex Pharmaceuticals and a pioneer of fragment-based drug discovery (FBDD). His work established fragment-based methods as a mainstream approach to cancer drug development and has yielded clinical candidates including ribociclib and other CDK inhibitors. Astex has produced multiple FDA-approved cancer drugs using FBDD combined with structural biology, validating this approach to designing potent and selective cancer therapeutics.